Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 expression
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
PD-L1 expression
Cervical Cancer
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
PD-L1 expression
Esophageal Cancer
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2wk
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2wk
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression
Solid Tumor
PD-L1 expression
Solid Tumor
pembrolizumab + MK-4280
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab + MK-4280
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab + MK-4280
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab + MK-4280
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Colorectal Cancer
PD-L1 expression
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
J Egypt Natl Canc Inst. - 4 weeks (New C3)
Immunotherapy
Sensitive
:
C3
J Egypt Natl Canc Inst. - 4wk
Immunotherapy
Sensitive: C3 – Early Trials
J Egypt Natl Canc Inst. - 4 weeks
Immunotherapy
Sensitive
:
C3
J Egypt Natl Canc Inst. - 4 weeks - (New C3)
PD-L1 expression
Breast Cancer
PD-L1 expression
Breast Cancer
Immunotherapy
Sensitive: C3 – Early Trials
J Egypt Natl Canc Inst. - 4 weeks (New C3)
Immunotherapy
Sensitive
:
C3
J Egypt Natl Canc Inst. - 4wk
Immunotherapy
Sensitive: C3 – Early Trials
J Egypt Natl Canc Inst. - 4 weeks
Immunotherapy
Sensitive
:
C3
J Egypt Natl Canc Inst. - 4 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Renal Cell Carcinoma
PD-L1 expression
Renal Cell Carcinoma
avelumab + axitinib
Sensitive: A1 - Approval
avelumab + axitinib
Sensitive
:
A1
avelumab + axitinib
Sensitive: A1 - Approval
avelumab + axitinib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Cervical Cancer
PD-L1 expression
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive: A1 - Approval
pembrolizumab + bevacizumab
Sensitive
:
A1
pembrolizumab + bevacizumab
Sensitive: A1 - Approval
pembrolizumab + bevacizumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
cemiplimab
Sensitive: A1 - Approval
cemiplimab
Sensitive
:
A1
cemiplimab
Sensitive: A1 - Approval
cemiplimab
Sensitive
:
A1
PD-L1 expression
Oral Cancer
PD-L1 expression
Oral Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Oropharyngeal Cancer
PD-L1 expression
Oropharyngeal Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Salivary Gland Cancer
PD-L1 expression
Salivary Gland Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
PD-L1 expression
Gastric Adenocarcinoma
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Bladder Cancer
PD-L1 expression
Bladder Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
PD-L1 expression
Bladder Cancer
PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Esophageal Adenocarcinoma
PD-L1 expression
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Renal Cell Carcinoma
PD-L1 expression
Renal Cell Carcinoma
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
PD-L1 expression
Head and Neck Cancer
PD-L1 expression
Head and Neck Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
bevacizumab + atezolizumab
Sensitive
:
A2
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
bevacizumab + atezolizumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login